Accepted Manuscript. Tolvaptan in Acute Heart Failure: Time to Move On. Randall C. Starling, MD MPH, James B. Young, MD
|
|
- Janice Warner
- 5 years ago
- Views:
Transcription
1 Accepted Manuscript Tolvaptan in Acute Heart Failure: Time to Move On Randall C. Starling, MD MPH, James B. Young, MD PII: S (16) DOI: /j.jacc Reference: JAC To appear in: Journal of the American College of Cardiology Received Date: 12 September 2016 Accepted Date: 13 September 2016 Please cite this article as: Starling RC, Young JB, Tolvaptan in Acute Heart Failure: Time to Move On, Journal of the American College of Cardiology (2016), doi: /j.jacc This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
2 Tolvaptan in Acute Heart Failure: Time to Move On Randall C. Starling, MD MPH; James B. Young MD Kaufman Center for Heart Failure Heart and Vascular Institute, Cleveland Clinic, Cleveland Ohio Short title: Tolvaptan in Acute Heart Failure Cover title: Time to Move On The authors have no relevant disclosures Corresponding Author: Randall C. Starling, MD, MPH Professor of Medicine Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University Kaufman Center for Heart Failure Robert and Susan Tomisch Department of Cardiovascular Medicine Heart and Vascular Institute Cleveland Clinic Cleveland Ohio Telephone: Fax:
3 Felker and colleagues succinctly and accurately describe the results of the TACTICS clinical trial in this issue of the journal. The methods for TACTICS and the SECRET of CHF Trials provide rationale for additional clinical investigation of the V2 arginine vasopression receptor antagonist tolvaptan. It was hypothesized that tolvaptan may allow for less intensification of loop diuretic therapy and a lower incidence of worsening renal function during treatment for congestive heart failure (1). Based on previous observations patients hospitalized with volume overload and symptomatic heart failure were randomized to a fixed dose of diuretic and placebo versus tolvaptan 30 mg given at 0, 24, and 48 hours with the stipulation that therapy was initiated within 24 hours of admission. The primary endpoint was a composite defined as responders based upon dyspnea relief and need for rescue therapy at 24 hours. The proportion defined as responders at 24 hours was similar between tolvaptan and placebo. Although this is a trial that did not achieve the primary endpoint (a negative trial) it is an important report and perhaps the final dialogue for the drug tolvaptan and its role in heart failure. There are now over 300 published reports cited in Pub Med when linking tolvaptan and heart failure. There are numerous published editorials since 2004 when Francis and Tang initially discussed the aquaretic tolvaptan; they encouraged the need for more data, and acknowledged the awaited results from the EVEREST trials (2,3). TACTICS, a well-designed and executed clinical trial, attempted to answer an important question that utilized hypothesis generating insights from numerous clinical trials with tolvaptan (4). It is also an expensive drug and value will, therefore, depend on the relationship of outcomes to cost. Though investigator initiated, the trial was sponsored by industry and currently the drug has a limited FDA approved indication for the treatment of clinically significant hyponatremia. It 2
4 was hypothesized that if dyspnea relief is confirmed then tolvaptan may be recognized as a much needed adjunctive therapy to safely treat congestion in patients with acute heart failure. Was the Hypothesis Valid? Yes Tolvaptan is an effective aquaretic drug that results in free water excretion. Tolvaptan has shown trends to reduce dyspnea better than placebo when given in the first 20 hours after hospitalization (5). Patients receiving tolvaptan versus placebo generally have greater weight loss and it was hoped would have lower requirements for loop diuretics and and hence less need for rescue therapy and improved 30 day outcomes. As loop diuretics are known to result in enhanced neurohormonal activity a reduced need for loop diuretics was expected to improve outcomes. The prespecified primary and secondary endpoints were all well aligned with the established body of knowledge regarding tolvaptan in heart failure. Tolvaptan did result in enhanced fluid and weight loss. Disappointingly the trial yielded negative results. What is the Future for Tolvaptan? There does not appear to be a justification for additional study of tolvaptan in acute or chronic heart failure. Despite greater weight and fluid loss, the pre specified endpoints were not met. Perhaps the current baseline for acute heart failure outcomes can be gleened from the ASCEND HF trial and the hope for the future is that serelaxin will provide incremental improvement (6,7). The authors concluded that the data from TACTICS-HF did not support an expansion beyond the current FDA indication for hyponatremia. Future Consideration and Acute Heart Failure We agree that effective treatment of acute heart failure represents an unmet need and that current strategies do not effectively reduce dyspnea or important endpoints including mortality and hospitalization compared with standard of care background therapy. Mechanical strategies 3
5 to remove free water, specifically ultrafiltration have been equally ineffective and the disconnect between weight/fluid loss and dyspnea is well described. It may be time to abandon the dyspnea endpoint in acute heart failure trials based on the difficulty of the measure and the uncertainty of its significance (8,9). Rolofylline reduced early dyspnea but this was dissociated with in-hospital worsening heart failure and outcomes at 60 and 180 days (10). The additional weight loss with tolvaptan did not reduce the tendency for inpatient worsening heart while hospitalized which is felt to represent an important clinical parameter in acute heart failure. he changes in renal function with tolvaptan were small, transient and do not merit further commentary or concern. In summary the TACTICS-HF provides extremely important data for clinicians and proves clearly that there is no benefit to the use of tolvaptan and its use should be discouraged based upon lack of efficacy and cost. The unmet need to develop better strategies for the treatment of acute heart failure remains a challenge and mandates ongoing investigation. 4
6 References 1. Felker GM, Mentz RJ, Adams KF, et al. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. Circ Heart Fail. 2015;8(5): Francis GS, Tang WH. Vasopressin receptor antagonists: will the "vaptans" fulfill their promise? JAMA. 2004;291(16): Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12): Felker GM, Mentz RJ, Cole R, et al. Efficacy and Safety of Tolvaptan in Patients Hospitalized with Acute Heart Failure J Am Coll Cardiol 2016;In press. 5. Pang PS, Konstam MA, Krasa HB, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30: O Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1): doi: /nejmoa Erratum in: N Engl J Med. 2011;365(8): Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860): West RL, Hernandez AF, O'Connor CM, Starling RC, Califf RM. A review of dyspnea in acute heart failure syndromes. Am Heart J. 2010;160(2):
7 9. Mentz RJ, Hernandez AF, Stebbins A, et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail. 2013;15(4): Metra M, O'Connor CM, Davison BA, et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J. 2011;32(12):
8
Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure
Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure Item Type info:eu-repo/semantics/article Authors Hernández, Adrian V. Citation Eur Heart J (2014) 35
More informationHyponatremia in Heart Failure: why it is important and what should we do about it?
Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationState of the Art Treatment - Hyponatremia, Heart Rate, et al
State of the Art Treatment - Hyponatremia, Heart Rate, et al Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from
More informationUri Elkayam, MD. Professor of Medicine University of Southern California Keck School of Medicine
Mihai Gheorghiade, MD Memorial Lecture Use of Vasopressin Antagonists for the Management of Hyponatremia and Volume Overload Uri Elkayam, MD Professor of Medicine University of Southern California Keck
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationEffect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF) Elizabeth Tien, PharmD, BCPS PGY2 Cardiology Pharmacy Resident Moses H. Cone Memorial Hospital Greensboro, NC Kristen Pogue,
More informationHow to define the target population?
Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationRaising expectations for Acute Heart Failure: What does the future bring to us?
Raising expectations for Acute Heart Failure: What does the future bring to us? Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland Speaker
More informationHeart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital
Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier
More informationNovel Natriuretic Peptides
Novel Natriuretic Peptides Frank Ruschitzka, MD, FRCP, FESC Professor of Cardiology Director, Heart Failure and Transplantation Clinic University Hospital Zürich, Switzerland Conflict of interest: Aventis,
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationThe Art and Science of Diuretic therapy
The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationThe LBCT of 2017 Heart Failure Trials. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
The LBCT of 2017 Heart Failure Trials Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA TRUE-AHF RELAX-AHF-2 Beta blockers in patients with HF with and without atrial fibrillation TRUE-AHF Additional Analysis
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationThe role of remote monitoring in preventing readmissions after acute heart failure
The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure
More informationexpert roundtable» Vasodilators in Acute Heart Failure: Who Needs Them and How Soon?
Article ID: CV13603 expert roundtable» Vasodilators in Acute Heart Failure: Who Needs Them and How Soon? Moderated by W. Frank Peacock, MD 1 Discussants: Alexandre Mebazaa, MD 2 ; John Teerlink, MD 3 ;
More informationTỐI ƯU HOÁ ĐIỀU TRỊ SUY TIM MẠN PGS. TS. CHÂU NGỌC HOA ĐHYD TPHCM
TỐI ƯU HOÁ ĐIỀU TRỊ SUY TIM MẠN PGS. TS. CHÂU NGỌC HOA ĐHYD TPHCM Signed by HFA / ESC/ HFSA/ ACC/ AHA Downloaded from http://circ.ahajournals.org/ at Amgen, Inc-- on May 20, 2016 3 In the year 2016, by
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Chronic type A dissection: when to operate? Francois Dagenais, MD PII: S0022-5223(18)33131-3 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.032 Reference: YMTC 13781 To appear in: The
More informationAldosterone Antagonist. Hyd/ISDN*
Μedical management of heart failure: Update 2014 Dr John T Parissis Attikon University Hospital Athens, Greece Disclosures: Received honoraria as consultant or research grants by Orion- Pharma, Servier,
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationUniversity of Groningen. Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena
University of Groningen Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationAccepted Manuscript. Prebiotics Versus Low Fodmap Diet: An Interpretative Nightmare. Jane Varney, Jane G. Muir, Peter R. Gibson
Accepted Manuscript Prebiotics Versus Low Fodmap Diet: An Interpretative Nightmare Jane Varney, Jane G. Muir, Peter R. Gibson PII: S0016-5085(18)35389-7 DOI: https://doi.org/10.1053/j.gastro.2018.10.060
More informationCongestion is the primary reason for hospitalization in
Advances in Clinical Trials Tolvaptan in Patients Hospitalized With Acute Heart Failure Rationale and Design of the TACTICS and the SECRET of CHF Trials G. Michael Felker, MD, MHS; Robert J. Mentz, MD;
More informationImpella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials
Accepted Manuscript Impella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials Dagmar M. Ouweneel, MSc, Erlend Eriksen, MD, Melchior Seyfarth,
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationMortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Judgement Day: Should You Add Atrial Fibrillation Ablation? Dr. Patrick M. McCarthy, MD PII: S0022-5223(18)32917-9 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.004 Reference: YMTC 13719
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationState-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.
State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. Heart Failure Exacerbates Renal Insufficiency ADHERE Registry: Prevalence of CKD by egfr
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Nitric Oxide: Might make it Better? J. Hunter Mehaffey, MD, MSc, Robert B. Hawkins, MD, MSc PII: S0022-5223(18)32342-0 DOI: 10.1016/j.jtcvs.2018.08.070 Reference: YMTC 13398 To appear
More informationBehandeling van Hartfalen: over 5 jaar
Behandeling van Hartfalen: over 5 jaar Adriaan Voors, cardioloog UMCG Over 5 jaar Heart Failure Treatment in 5 Years HFrEF: best evidence, biggest pipeline Entresto Omcamtiv LVAD: destination therapy HFrEF:
More informationLetter to the Editor: Response to Updated Clinical Classification of Pulmonary Hypertension
Accepted Manuscript Letter to the Editor: Response to Updated Clinical Classification of Pulmonary Hypertension Elizabeth S. Klings, MD Claudia R. Morris, MD Lewis Hsu, MD, PhD Oswaldo Castro, MD Mark
More informationSlide 1. Slide 2. Slide 3. Managing Acute Heart Failure Trials and Tribulations. Declaration of
Slide 1 Managing Acute Heart Failure Trials and Tribulations Martin R Cowie MD MSc FRCP FRCP (Ed) FESC Professor of Cardiology, Imperial College London m.cowie@imperial.ac.uk @ProfMartinCowie Slide 2 Declaration
More informationManagement of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University
Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association
More informationResponse to Authors Concern for Mischaracterization of Referenced Publications
Accepted Manuscript Response to Authors Concern for Mischaracterization of Referenced Publications Catherine C. Motosko, BS, George A. Zakhem, BS, Anna K. Ault, BA, Laura L. Kimberly, MSW, MBE, M David
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Pacemaker Or No Pacemaker? The Question of a Lifetime Carlos M. Mery, MD, MPH, Daniel P. Shmorhun, MD PII: S0022-5223(18)32862-9 DOI: https://doi.org/10.1016/j.jtcvs.2018.10.088 Reference:
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript The mid-life crisis of the meta-analysis Joanna Chikwe, MD, FRCS, Aaron Weiss, MD PII: S0022-5223(18)33158-1 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.045 Reference: YMTC 13805 To
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Scylla versus Charybdis: the eternal dilemma continues Vivek Rao, MD, PhD PII: S0022-5223(18)32088-9 DOI: 10.1016/j.jtcvs.2018.07.092 Reference: YMTC 13320 To appear in: The Journal
More informationChristopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor
New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University
More informationAcute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm
Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen Helsinki, Finland M S Nieminen, AHF 300810,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen
More informationAccepted Manuscript. Extracorporeal Membrane Oxygenation for Septic Shock: Heroic Futility? Francis D. Pagani, MD PhD
Accepted Manuscript Extracorporeal Membrane Oxygenation for Septic Shock: Heroic Futility? Francis D. Pagani, MD PhD PII: S0022-5223(18)31214-5 DOI: 10.1016/j.jtcvs.2018.04.076 Reference: YMTC 12949 To
More informationRecent therapeutic trials on fluid removal and vasodilation in acute heart failure
560504ACC0010.1177/2048872614560504European Heart Journal: Acute Cardiovascular CareEnnezat et al. research-article2014 Review Recent therapeutic trials on fluid removal and vasodilation in acute heart
More informationThe Association of Hyponatremia with Race, Ethnicity, and Gender in Patients Admitted for Acute Decompensated Heart Failure Diagnoses
Thomas Jefferson University Jefferson Digital Commons Division of Internal Medicine Faculty Papers & Presentations Division of Internal Medicine 2018 The Association of Hyponatremia with Race, Ethnicity,
More informationMY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
More informationCommentary:Right Ventricular-Tricuspid Valve Interdependance And The Challenges For Structural Heart Valve Therapy
Accepted Manuscript Commentary:Right Ventricular-Tricuspid Valve Interdependance And The Challenges For Structural Heart Valve Therapy Amedeo Anselmi, MD PhD PII: S0022-5223(19)30021-2 DOI: https://doi.org/10.1016/j.jtcvs.2018.12.094
More informationAccepted Manuscript. A Bad Trade: Mitral Regurgitation for Mitral Stenosis and Atrial Fibrillation
Accepted Manuscript A Bad Trade: Mitral Regurgitation for Mitral Stenosis and Atrial Fibrillation Marc Gillinov, MD, Per Wierup, MD, PhD, Stephanie Mick, MD PII: S0022-5223(18)32281-5 DOI: 10.1016/j.jtcvs.2018.08.036
More informationThe Journal of Thoracic and Cardiovascular Surgery
Accepted Manuscript Mesothelioma: Live to Fight Another Day Andrea S. Wolf, MD, Raja M. Flores, MD PII: S0022-5223(17)32747-2 DOI: 10.1016/j.jtcvs.2017.11.060 Reference: YMTC 12301 To appear in: The Journal
More informationComments on GUIDE-IT, a randomized study of natriuretic peptide-guided therapy in high-risk patients with heart failure and reduced ejection fraction
Editorial Page 1 of 5 Comments on GUIDE-IT, a randomized study of natriuretic peptide-guided therapy in high-risk patients with heart failure and reduced ejection fraction Wouter E. Kok Cardiology Department,
More informationBioprosthetic aortic valve replacement: a high standard of comparison for transcatheter aortic valve implantation
Accepted Manuscript Bioprosthetic aortic valve replacement: a high standard of comparison for transcatheter aortic valve implantation Aaron Martin, MD, Michael H. Yamashita, MDCM, MPH PII: S0022-5223(18)32910-6
More informationAccepted Manuscript. Robotic tracheobronchoplasty is feasible but which patients truly benefit? Steven Milman, MD, Thomas Ng, MD
Accepted Manuscript Robotic tracheobronchoplasty is feasible but which patients truly benefit? Steven Milman, MD, Thomas Ng, MD PII: S0022-5223(18)32271-2 DOI: 10.1016/j.jtcvs.2018.08.028 Reference: YMTC
More informationControversial issues in heart failure. Can we change the outcome of patients with acute heart failure?
Controversial issues in heart failure Can we change the outcome of patients with acute heart failure? Marco Metra, MD, FESC Associateprofessor of Cardiology. University of Brescia The Burden of Acute HF
More informationAccepted Manuscript. Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Disconnect Between Logic and Data?
Accepted Manuscript Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Disconnect Between Logic and Data? Azeem Latib, MD, Matteo Pagnesi, MD PII: S0735-1097(16)36808-5 DOI: 10.1016/j.jacc.2016.10.036
More informationAccepted Manuscript. The Aorta in Repaired Tetralogy of Fallot: A Potential Source of Late Danger? Joseph B. Clark, MD
Accepted Manuscript The Aorta in Repaired Tetralogy of Fallot: A Potential Source of Late Danger? Joseph B. Clark, MD PII: S0022-5223(18)32548-0 DOI: 10.1016/j.jtcvs.2018.09.044 Reference: YMTC 13498 To
More informationCHF and Managing Post Hospital
CHF and Managing Post Hospital Nancy Mesiha, MD, FACC, MACM PD, Cardiovascular Fellowship Program St John Hospital & Medical Center Cardiology Associates of Michigan S No Disclosures Objectives S Statistics
More informationAccepted Manuscript. Current State of the Art for the Surgical Management of empyema thoracis. K. Robert Shen, M.D.
Accepted Manuscript Current State of the Art for the Surgical Management of empyema thoracis K. Robert Shen, M.D. PII: S0022-5223(18)32919-2 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.006 Reference:
More information9/24/2010 S U ts n ) s tie a 4.7 illio (m 3.5 ilu rt F a Outpatient e H Inpatient * 50 s 60 s 70 s >80
Exciting Times: Advances in Heart Failure Dana McGlothlin, MD Associate Professor of Medicine Advanced Heart Failure and Transplant Program Medical Director, CCU Overview HF Statistics Therapies for chronic
More informationSamsca. Samsca (tolvaptan) Description
Subject: Samsca Page: 1 of 5 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: September 20, 2018 Samsca Description Samsca (tolvaptan)
More informationAccepted Manuscript. The Challenges of Big Data in Dermatology. Megan H. Noe, MD, MPH, Arash Mostaghimi, MD, MPA, MPH
Accepted Manuscript The Challenges of Big Data in Dermatology Megan H. Noe, MD, MPH, Arash Mostaghimi, MD, MPA, MPH PII: S0190-9622(18)30664-9 DOI: 10.1016/j.jaad.2018.03.059 Reference: YMJD 12511 To appear
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationIn the acute care setting, dyspnea is the most commonly
Hemodynamic Determinants of Dyspnea Improvement in Acute Decompensated Heart Failure Amir Solomonica, MD, MPH; Andrew J. Burger, MD; Doron Aronson, MD Background Dyspnea relief constitutes a major treatment
More informationClinical Pathways Heart Failure Webinar AMGA May
Clinical Pathways Heart Failure Webinar AMGA May 31 2016 Randall C. Starling, MD, MPH, FACC,FESC Professor Of Medicine Heart Failure and Cardiac Transplant Medicine Heart and Vascular Institute Cleveland
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationAccepted Manuscript. Does valve choice matter in hemodialysis patients? Weiang Yan, MD, Rakesh C. Arora, MD, PhD, Michael H. Yamashita, MDCM, MPH
Accepted Manuscript Does valve choice matter in hemodialysis patients? Weiang Yan, MD, Rakesh C. Arora, MD, PhD, Michael H. Yamashita, MDCM, MPH PII: S0022-5223(18)32559-5 DOI: 10.1016/j.jtcvs.2018.09.055
More informationAccepted Manuscript. Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA)
Accepted Manuscript Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA) Joseph S. Alpert MD, Rokas Serpytis MD, Pranas Serpytis MD, Qin M. Chen PhD PII: S0002-9343(18)31183-5 DOI: https://doi.org/10.1016/j.amjmed.2018.12.005
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationTalking points included in this deck are for internal/speaker use only, and are not to be distributed.
1 Talking points included in this deck are for internal/speaker use only, and are not to be distributed. Before presenting the CHAMPION study, I would like to provide a brief overview of the CardioMEMS
More informationROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association
ROSE-AHF and Beyond Gerasimos Filippatos, FESC, FHFA President Heart Failure Association From: Braunwald s Heart Disease. 9th ed. Philadelphia, Elsevier, 2011 Determinants and forms of worsening renal
More informationAccepted Manuscript. MAC: Mitral Annular Calcification or a Modern Approach to Concept learning in surgery
Accepted Manuscript MAC: Mitral Annular Calcification or a Modern Approach to Concept learning in surgery Serge Kobsa, MD, PhD, Hiroo Takayama, MD, PhD PII: S0022-5223(18)31805-1 DOI: 10.1016/j.jtcvs.2018.06.058
More informationAccepted Manuscript. The Golden Ratio. Tomasz A. Timek, MD PhD
Accepted Manuscript The Golden Ratio Tomasz A. Timek, MD PhD PII: S0022-5223(19)30016-9 DOI: https://doi.org/10.1016/j.jtcvs.2018.12.089 Reference: YMTC 13991 To appear in: The Journal of Thoracic and
More informationAccepted Manuscript. Surgery for mesothelioma: less is more, more or less. Steven Milman, MD, Thomas Ng, MD
Accepted Manuscript Surgery for mesothelioma: less is more, more or less Steven Milman, MD, Thomas Ng, MD PII: S0022-5223(17)32706-X DOI: 10.1016/j.jtcvs.2017.11.029 Reference: YMTC 12266 To appear in:
More informationAccepted Manuscript. Improving Survival in Cardiogenic shock: Is Impella the Answer?,, James J Glazier MD, Amir Kaki MD S (18)
Accepted Manuscript Improving Survival in Cardiogenic shock: Is Impella the Answer?,, James J Glazier MD, Amir Kaki MD PII: S0002-9343(18)30496-0 DOI: 10.1016/j.amjmed.2018.04.045 Reference: AJM 14684
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationTherapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
J Pharmacol Sci 124, 000 000 (2014) Journal of Pharmacological Sciences The Japanese Pharmacological Society Current Perspective Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
More informationIn surgery for acute type A aortic dissection, follow the principles and do what you need to do
Accepted Manuscript In surgery for acute type A aortic dissection, follow the principles and do what you need to do Ourania Preventza, MD, Kim I. de la Cruz, MD, Joseph S. Coselli, MD PII: S0022-5223(19)30705-6
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationEditorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD
Accepted Manuscript Editorial commentary: Size and margin do matter, but is it the whole story? Paul A.J. Beckers, MD, Lawek Berzenji, MD,, Paul E. Van Schil, MD, PhD PII: S0022-5223(18)33135-0 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.036
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 7 Last Review Status/Date: September 2016 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationObjectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney
Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the
More informationAccepted Manuscript. Wound Management Strategies in Stevens-Johnson syndrome/toxic Epidermal Necrolysis: An unmet need
Accepted Manuscript Wound Management Strategies in Stevens-Johnson syndrome/toxic Epidermal Necrolysis: An unmet need Lee Haur Yueh, MBBS, MRCP, MMed, FAMS PII: S0190-9622(18)32138-8 DOI: 10.1016/j.jaad.2018.05.1258
More informationAccepted Manuscript. Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer. Jessica S. Donington, MD, MSCR
Accepted Manuscript Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer Jessica S. Donington, MD, MSCR PII: S0022-5223(18)32903-9 DOI: https://doi.org/10.1016/j.jtcvs.2018.10.124 Reference:
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationWhy to use digoxin in heart failure?
Why to use digoxin in heart failure? Yves Juillière, Cardiology, ILCV, CHU Nancy-Brabois, France Digitalis purpurea Representation of the extracellular loops and the transmembrane domain regions of the
More informationGerasimos Filippatos MD, FESC, FCCP, FACC
Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation Nielsen, Peter Brønnum; Skjøth, Flemming; Rasmussen, Lars Hvilsted; Larsen, Torben Bjerregaard; Lip, Gregory DOI: 10.1016/j.cjca.2015.01.034
More informationAccepted Manuscript. Coronary dialysis patients: CABG or PCI? A complex question for a complex scenario
Accepted Manuscript Coronary dialysis patients: CABG or PCI? A complex question for a complex scenario Francesco Formica, MD, Stefano D Alessandro, MD, FECTS. PII: S0022-5223(18)32554-6 DOI: 10.1016/j.jtcvs.2018.09.050
More informationFrom Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs Florence Wong University of Toronto Falk Symposium October 14, 2007 Sodium Retention in Cirrhosis Occurs as a result of hemodynamic
More informationExtent of lymphadenectomy for esophageal squamous cell cancer: interpreting the post-hoc analysis of a randomized trial
Accepted Manuscript Extent of lymphadenectomy for esophageal squamous cell cancer: interpreting the post-hoc analysis of a randomized trial Vaibhav Gupta, MD PII: S0022-5223(18)33169-6 DOI: https://doi.org/10.1016/j.jtcvs.2018.11.055
More informationStopping the Revolving Door of ADHF
Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center
More information